Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
Young Kul Jung, Ju Hyun Kim
Clin Mol Hepatol. 2013;19(1):26-28. Published online 2013 Mar 25 DOI: https://doi.org/10.3350/cmh.2013.19.1.26
Citations to this article as recorded by 
Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C
Jae-Won Lee, Won Kim, Eun-Kyung Kwon, Yuri Kim, Hyun Mu Shin, Dong-Hyun Kim, Chan-Ki Min, Ji-Yeob Choi, Won-Woo Lee, Myung-Sik Choi, Byeong Gwan Kim, Nam-Hyuk Cho, Eui-Cheol Shin
PLOS ONE.2017; 12(6): e0179094. CrossRef
Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong
Gut and Liver.2017; 11(4): 543. CrossRef
Phylogeny and molecular evolution of the hepatitis C virus
Paulina Jackowiak, Karolina Kuls, Lucyna Budzko, Anna Mania, Magdalena Figlerowicz, Marek Figlerowicz
Infection, Genetics and Evolution.2014; 21: 67. CrossRef
No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
Nae-Yun Heo, Young-Suk Lim, Woochang Lee, Minkyung Oh, Jiyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Yung Sang Lee, Dong Jin Suh
Clinical and Molecular Hepatology.2014; 20(2): 177. CrossRef